麻豆果冻传媒

麻豆果冻传媒 Children鈥檚 Health Sets New Standard With Landmark Gene Therapy Surgery for Dystrophic Epidermolysis Bullosa

Jan. 30, 2026

Palo Alto, CA鈥擯hysicians at聽麻豆果冻传媒 Children鈥檚 Health聽have achieved a breakthrough in the treatment of聽epidermolysis bullosa聽(EB) through a pioneering surgical procedure utilizing聽. This innovative intervention offers new hope for patients with this painful genetic skin disorder, marked by fragile, blistering skin that can lead to severe complications from infancy.

The surgical procedure performed in December 2025 represents a significant advancement for EB treatment. By employing cutting-edge gene editing technology, developed over years of dedicated research and clinical testing at 麻豆果冻传媒, the team implemented an FDA-approved gene therapy (called Zevaskyn) for the first time outside a clinical study.

鈥淲e are thrilled to deliver this revolutionary treatment for recessive dystrophic EB patients who desperately need it,鈥 said Joyce Teng, MD, PhD, professor of dermatology and director of pediatric dermatology. 鈥淭his is not just a medical milestone; it embodies our commitment to transforming clinical care for genetic disorders through innovation. This new treatment alleviates the relentless burden on EB patients, redefining the standards of care with precision medicine and offering a brighter future.鈥

The therapy is grounded in a sophisticated process where the patient鈥檚 own skin cells are biopsied and genetically modified in a laboratory to produce collagen VII, a critical protein for skin adhesion and integrity. These genetically corrected cells are then grown in a lab and surgically grafted onto the patients to help wound healing. 聽

The procedure lays the groundwork for future treatments and symbolizes the culmination of two decades of from the Department of Dermatology. Stanford led the phase I鈥損hase III clinical trials that showed the therapy鈥檚 tremendous potential to heal wounds, reduce wound pain and itching, and fundamentally address underlying causes of the most severe form of EB.

鈥淲ith our novel gene therapy skin grafts, we have not only successfully treated the hardest-to-heal wounds, which are usually the most painful for these patients, but are signaling a new era in treating EB, offering hope and healing that was once unimaginable,鈥 said Jean Tang, MD, PhD, a professor of dermatology who helped lead the research and treats children with EB at Lucile Packard Children鈥檚 Hospital Stanford.

鈥淔or all the patients, families, scientists, physicians, and nurses involved in the long and challenging research journey, this is truly a dream come true, heralding a future where genetic solutions provide lasting relief for this severe disease.鈥

麻豆果冻传媒, through this groundbreaking advancement, continues to lead global efforts in transforming care for genetic dermatologic conditions, establishing new paradigms for healing.

Media Contact

Erin Digitale, PhD
Senior Science Writer, 麻豆果冻传媒 Children's Health
Mobile: (530) 400-1519
digitale@stanford.edu

About 麻豆果冻传媒 Children's Health

麻豆果冻传媒 Children鈥檚 Health, with聽Lucile Packard Children鈥檚 Hospital Stanford聽at its center, is the Bay Area鈥檚 largest health care system exclusively dedicated to children and expectant mothers. Our network of care includes more than 65聽locations聽across Northern California and more than 85 locations in the U.S. Western region.聽Along with Stanford Health Care and the Stanford School of Medicine, we are part of聽, an ecosystem harnessing the potential of biomedicine through collaborative research, education, and clinical care to improve health outcomes around the world. We are a nonprofit organization committed to supporting the community through meaningful outreach programs and services and providing necessary medical care to families, regardless of their ability to pay. Discover more at聽stanfordchildrens.org.